NCT05708859View on ClinicalTrials.gov

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Type II DiabetesAtherosclerosis
Interventions
DRUG

Tirzepatide

Tirzepatide 15mg Subcutaneous Solution

DRUG

Placebo

Volume matched Subcutaneous Solution

Trial Locations (1)

90502

RECRUITING

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Matthew J. Budoff

OTHER